Navigation Links
Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Date:5/29/2008

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL) reported that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did not meet statistical significance for the primary endpoint of survival in unresectable malignant mesothelioma (UMM). However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen.

The preliminary results are based on 320 evaluable events that occurred in the clinical trial out of a total of 428 patients randomized. The trial was designed to show a statistically significant improvement in overall survival (p < 0.048) for UMM patients who were treated with a combination of ONCONASE plus doxorubicin as compared to patients who were treated with doxorubicin as a single agent. The analysis of the data did not show a statistically significant improvement for evaluable patients receiving ONCONASE plus doxorubicin (unadjusted log rank p=0.80). The median survival time (MST) for evaluable patients who received ONCONASE plus doxorubicin was 11.1 months as compared to 10.7 months for patients who received doxorubicin as a single agent.

Statistically significant results were achieved in evaluable UMM patients who failed a prior chemotherapy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) ... of schizophrenia and manic or mixed episodes associated with ... ,, The updated Zyprexa label states that clinicians ... gain and hyperlipidemia in adolescents compared to adults and ...
(Date:12/4/2009)... (Pink Sheets: VRMLQ) announced that on December 3, 2009, it ... Disclosure Statement with the United States Bankruptcy Court for the ... the adequacy of the Disclosure Statement is presently scheduled for ... the Plan scheduled for January 7, 2010. ,, "We are ...
(Date:12/4/2009)... Dec. 4 Amber Pharmacy announced today that it ... Inc. (ACHC) for specialized pharmacy services. For nearly 15 ... and services to meet the unique needs of specialized ... of services to transplant programs. They work with over ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Amber Pharmacy Earns Accreditation From ACHC 2STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 1STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 2STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 3STEMCELL Technologies Inc Announces Direct Distribution to Spain 59120 4Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 59118 1Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 59118 2Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 1Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 2Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 3
... AACR Meeting Highlights Potential Therapeutic Approach to Treat ... Micromet, Inc. (Nasdaq: MITI ), ... the treatment of cancer, inflammation and autoimmune diseases, ... of the American Association for Cancer Research (AACR). ...
... for Cancer Research -PRINCETON, N.J., April 21 ... announced preclinical efficacy and safety data from multiple ... cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, CD70) and ... Data from the studies were presented at the ...
Other Medicine Technology:Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 2Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 3Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells 4Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 2Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 3Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 4
(Date:12/6/2009)... researchers from the Medical College of Wisconsin, in Milwaukee, ... and other sickle cell disease complications in children. Barriers ... and patients were also identified. The study led ... pediatrics at the Medical College and Children,s Research Institute ... at the American Society of Hematology meeting Dec. 7, ...
(Date:12/6/2009)... site www.sleeping-with-a-sleeping-disorder.com is asking people ,who ... sleep aids from around the world to donate ... The submissions will be compiled in an ebook ... to be sold from the website in early ... the proceeds ,from sales of the E-book to ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: To ... terminal illnesses affecting children. All proceeds from each hair service ... Guests will enjoy complimentary beverages and hors d,oeuvres, provided by ... Church for all guests. Hoa Lai, a DJ known for ...
(Date:12/5/2009)... being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- ... without ever tying the knot, since research has shown that ... um, isn,t there something wrong with those who go it ... looking at psychological measures shows that never-married people aged 40 ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
... by 50%, study concludes, , , MONDAY, April 7 ... offer nutrition education and reward students for nutritious ... preventing childhood obesity, according to a Temple University ... multifaceted nutrition program reduced the number of overweight ...
... science education, scientific research, and the role science should play in ... ... NEW YORK, April 7, 2008 Since its launch in October,2006, the ... human health issues facing the 21st century, including the,brain, the human genome, ...
... Schizophrenia is a complex type of psychotic mental ... Huge gains in the effective treatment of individuals with ... of the first generation of antipsychotic drugs. The medications ... illness (delusions and hallucinations) and, to a lesser extent, ...
... SCRANTON, Pa., April 7, 2008 Penn Foster ... build essential skills,for working professionals. The program offerings ... -- Anatomy and Physiology, This broad ... working adults in,the health professions. Prospective nurses, medical ...
... is high in the antioxidant EGCG (epigallocatechin-3- gallate) which ... prematurely aged. Studies have suggested that the combination of ... providing protection against certain types of cancers, including breast ... University of Mississippi researchers now finds that consuming EGCG ...
... Enjoy His Young Family,and Active Life, MIDDLE ISLAND, ... Trade Center on September 11, 2001, New York,City Patrolman ... Now,more than seven years later, O,Connor needs help overcoming ... later in,the line of duty., At 32, Mr. ...
Other Medicine News:Health News:School Environment Can Curb Kids' Weight Gain 2Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 2Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 3Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 2Health News:Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected 3Health News:Penn Foster Career School Offers Certificate Programs 2Health News:Ingredient found in green tea significantly inhibits breast cancer growth in female mice 2Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 2Health News:The SCOOTER Store Donates Power Scooter to Former NYPD Officer Who Responded to 9/11 3
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
... As a pioneer in the design and ... extraction of viscous fluids, D.O.R.C. is pleased ... combination of injection and extraction in one ... controlled injection of viscous fluids, such as ...
... Wash both 96- and 384-well plates ... Strip Washer. As a self contained ... for full control of precise fluidic ... a simple squeeze bottle to the ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
Medicine Products: